France’s TxCell (Euronext Paris: TXCL) announced late Monday that it has exercised its exclusive option to in-license the intellectual property rights of one of its academic partners, the University of British Columbia (UBC), onto the HLA-A2 CAR-Treg program.
This program, named TX200 in TxCell's portfolio, should soon be tested in humans in the prevention of chronic transplant rejection. A first clinical trial application (CTA) is expected to be actioned in Europe in the first part of 2019.
The product originated in the laboratories of Dr Megan Levings, UBC in Vancouver, Canada, who established the first preclinical proof of concept with human HLA-A2-specific CAR-Treg cells in a preclinical model of GvHD.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze